Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Alexandros Marios Sofias, Twan Lammers(RWTH Aachen University), Yang Shi(Guiyang College of Traditional Chinese Medicine), Fabian Kießling(Universitätsklinikum Aachen), Federica De Lorenzi(Theranostics (New Zealand)), Jiong‐Wei Wang(National University of Singapore), Armin Azadkhah Shalmani(Theranostics (New Zealand)), Mihael Vucur(Düsseldorf University Hospital), Quim Peña(DWI – Leibniz Institute for Interactive Materials), Gert Storm(Yong In University), Lorena Consolino(University of Turin)
Cited by 26
Related Papers
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Tumor targeting via EPR: Strategies to enhance patient responses
|Advanced Drug Delivery Reviews|2018|1.2k
Smart cancer nanomedicine
|Nature Nanotechnology|2019|1.2k
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis
|Hepatology|2010|791